Page 68 - Read Online

Page 14 of 15 Li et al. Hepatoma Res. 2026;12:36

22. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular
carcinoma. Hepatology. 2002;35:1164-71. DOI PubMed
23. Zhu HD, Liu R, Jia ZZ, et al. Transarterial chemoembolization for hepatocellular carcinoma: treatment algorithm proposed by Chinese
College of Interventionalists(CCI). EngMedicine. 2024;1:1-9. DOI
24. Miyayama S, Matsui O. Superselective conventional transarterial chemoembolization for hepatocellular carcinoma: rationale, technique,
and outcome. J Vasc Interv Radiol. 2016;27:1269-78. DOI PubMed
25. de Baere T, Ronot M, Chung JW, et al. Initiative on superselective conventional transarterial chemoembolization results (INSPIRE).
Cardiovasc Intervent Radiol. 2022;45:1430-40. DOI PubMed PMC
26. Liu B, Gao S, Guo J, et al. Efficacy and safety of hepasphere drug-eluting bead transarterial chemoembolization combined with hepatic
arterial infusion chemotherapy as the second-line treatment in advanced hepatocellular carcinoma. J Hepatocell Carcinoma.
2024;11:477-88. DOI PubMed PMC
27. Gjoreski A, Popova-Jovanovska R, Eftimovska-Rogac I, Vejseli J. Safety profile and efficacy of chemoembolization with doxorubicin -
loaded polyethylene glycol microspheres in patients with hepatocellular carcinoma. Open Access Maced J Med Sci. 2019;7:742-6. DOI
PubMed PMC
28. Lin CY, Liu YS, Pan KT, Chen CB, Hung CF, Chou CT. The short-term safety and efficacy of TANDEM microspheres of various sizes
and doxorubicin loading concentrations for hepatocellular carcinoma treatment. Sci Rep. 2021;11:12277. DOI PubMed PMC
29. Vogl TJ, Lammer J, Lencioni R, et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with
PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol.
2011;197:W562-70. DOI PubMed
30. Ayyub J, Dabhi KN, Gohil NV, et al. Evaluation of the safety and efficacy of conventional transarterial chemoembolization (cTACE)
and drug-eluting bead (DEB)-TACE in the management of unresectable hepatocellular carcinoma: a systematic review. Cureus.
2023;15:e41943. DOI PubMed PMC
31. Shi D, Ren Y, Liu Y, et al. Temperature-sensitive nanogels combined with polyphosphate and cisplatin for the enhancement of tumor
artery embolization by coagulation activation. Acta Biomater. 2024;185:240-53. DOI PubMed
32. Li Q, Shi J, Ruan X, et al. Hypoxia‐ and pH‐responsive metal‐phenolic network‐engineered ferroptosis‐immuno microspheres for
transarterial chemoembolization in hepatocellular carcinoma. Adv Funct Mater. 2025;35:e10798. DOI
33. Wen K, Ren Y, Huang J, et al. Dual-stage drug delivery microspheres amplify tumor starvation through coagulation-enhanced vascular
occlusion. Small. 2025;21:e08070. DOI PubMed
34. Zhang M, Zhou J, Jiang X, et al. MoS 2 nanozyme-chlorella hydrogels: pioneering a hepatocellular carcinoma integrative therapy. Adv
Funct Mater. 2025;35:2417125. DOI
35. Xu J, Pei Z, Wang Y, et al. Bioactive microspheres to enhance sonodynamic-embolization-metalloimmune therapy for orthotopic liver
cancer. Biomaterials. 2025;317:123063. DOI PubMed
36. Yang N, Sun X, Zhou Y, et al. Liquid metal microspheres with an eddy-thermal effect for magnetic hyperthermia-enhanced cancer
embolization-immunotherapy. Sci Bull. 2023;68:1772-83. DOI PubMed
37. Llovet JM, Ricci S, Mazzaferro V, et al. ; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 2008;359:378-90. DOI PubMed
38. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:
a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163-73. DOI PubMed
39. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung
metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2
and VEGF-R3 kinase. Clin Cancer Res. 2008;14:5459-65. DOI PubMed
40. Li X, Qiu M, Wang S, Zhu H, Feng B, Zheng L. A phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in
patients with advanced solid tumours. Cancer Chemother Pharmacol. 2020;85:593-604. DOI PubMed
41. Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised,
multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23:77-90. DOI PubMed
42. Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for
unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862-73. DOI PubMed PMC
43. Rimassa L, Chan SL, Sangro B, et al. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab
in unresectable HCC. J Hepatol. 2025;83:899-908. DOI PubMed
44. Yau T, Galle PR, Decaens T, et al. ; CheckMate 9DW investigators. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-
line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet.
2025;405:1851-64. DOI PubMed